Sign up Australia
Proactive Investors - Run By Investors For Investors

Medical Australia to acquire animal stem cell technology company MediVet

Medical Australia to acquire animal stem cell technology company MediVet

Medical Australia (ASX: MLA) has now signed an agreement to acquire Medivet Pty Ltd, which is a private Australian company with proprietary ownership technology for regenerative stem cell technology for domestic animals and the equine industry.

Consideration for the deal will by around 36.6 million shares at $0.30 for total consideration of $11 million.

MLA announced in June this year that it intended to acquire MediVet for $10 million in a 50/50 cash and scrip transaction.

The latest agreement has been executed in order to provide a quicker close so immediate business opportunities can be pursued. The acquisition is subject to shareholder approval.

The acquisition by MLA is company transforming, and it creates a unique and profitable human and animal healthcare company with a global footprint.


MediVet back story

Founded in 2008, MediVet is a leader in the animal healthcare market and has developed a range of animal healthcare products which are highly regarded in a number of global markets.

The company is best known for developing the world-first in house regenerative animal stem-cell technology which has been commercialised for the veterinary and equine markets throughout the world.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.





Register here to be notified of future MLA Company articles
View full MLA profile View Profile

Medical Australia Timeline

Related Articles

stem cell
June 12 2017
"With multiple value upside triggers ahead, including imminent maiden revenues from CellPlan, I very much look forward to the opportunities ahead" - CEO João Andrade
gauge
July 26 2017
We hope this will be the first of many product launches of multiple formulations and presentations of LP-LDL as the active component in a wide range of pharmaceutical and consumer products around the world - chief executive Stephen O’Hara
ventripoint_device.png
June 22 2017
The device can give accurate and rapid volumetric information about all four chambers of the heart

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use